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Abstract
Cysteine proteases of the papain superfamily are present in nearly all eukaryotes. They play pivotal roles in the
biology of parasites and inhibition of cysteine proteases is emerging as an important strategy to combat parasitic
diseases such as sleeping sickness, Chagas’ disease and leishmaniasis. Homology modeling of the mature
Leishmania mexicana cysteine protease CPB2.8 suggested that it differs significantly from bovine cathepsin B and
thus could be a good drug target. High throughput screening of a compound library against this enzyme and bovine
cathepsin B in a counter assay identified four novel inhibitors, containing the warhead-types semicarbazone,
thiosemicarbazone and triazine nitrile, that can be used as leads for antiparasite drug design. Covalent docking
experiments confirmed the SARs of these lead compounds in an effort to understand the structural elements required
for specific inhibition of CPB2.8. This study has provided starting points for the design of selective and highly potent
inhibitors of L. mexicana cysteine protease CPB that may also have useful efficacy against other important cysteine
proteases.
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Introduction
Current drug therapy for the treatment of neglected diseases
associated with parasitic protozoa mainly relies on drugs
developed decades ago. Severe toxic effects combined with
the emergence of drug resistant parasite strains create an
urgent and continuous need for new, safe and effective drugs
against leishmaniasis [1,2]. Cysteine proteases constitute a
pivotal class of enzymes that play numerous roles in the
biology of these trypanosomatid parasites [3,4]. Identification
and further characterization of cysteine protease-mediated
processes in parasitic protozoa is progressing [5-7] and
supporting the idea that a possible strategy for combating
parasitic infections is to inhibit cysteine proteases that are
crucial to parasite metabolism and reproduction. Papain-like
cysteine proteases have been identified in T. cruzi (cruzain) [8],
T. brucei (trypanopain, TbCatB) [9] and different Leishmania
spp. (CPA, CPB, CPC) [10,11] and inhibition of these
peptidases has led to promising results both in vitro [12], in
tissue culture models [13-15] and in vivo [15-17]. This study
has focused on finding inhibitors of CPB, a cathepsin L-like
cysteine protease thought to be crucial in the infectivity of
Leishmania mexicana and encoded as a tandem array of 19
similar genes [18]. CPB expression is regulated so that CPB1
and CPB2, the first two genes of the tandem array, are
expressed in the infectious metacyclic stage and the remaining
genes in the intracellular amastigote stage that causes the
disease [19]. Due to their high sequence identity [20], the
multiple isoforms present in amastigotes are expected to have
similar inhibitor susceptibilities. A recombinant form of the
amastigote-specific isoform CPB2.8, expressed without the C-
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terminal extension and so designated CPB2.8∆CTE [21], was
used in this study.
Inhibitors of cysteine proteases typically rely on the presence
of a warhead, an electrophilic functionality that is attacked by
the catalytic cysteine thiolate in the active site of the target
enzyme [22-24]. Inhibitors containing a reversible reactive
warhead-type might be expected to possess better safety
profiles with regards to their potential application as drugs for
treating parasitic infections, examples of such reactive
inhibitors of L. mexicana CPB are compounds of the class of α-
ketoheterocycles [25]. In order to identify new warhead-types
that are reversibly reactive and have some specificity for
cysteine proteases of trypanosomatid parasites, high
throughput screening of a compound library against L.
mexicana CPB2.8 and bovine cathepsin B as a counter assay
was performed. Homology modeling and covalent docking
studies to rationalize the experimental findings were also
carried out. Thus, it was established that semicarbazones,
thiosemicarbazones and triazine nitriles are competitive
inhibitors of L. mexicana CPB2.8∆CTE.
Results
Homology modeling of L. mexicana CPB2.8∆CTE
In order to get the protein’s 3D structure for covalent docking
studies and subsite residue determination, a structural model of
mature L. mexicana CPB2.8∆CTE using comparative modeling
was generated [26]. Due to its excellent structure resolution of
1.75 Å and low B-factors [27], cruzain (PDB ID 1EWP) co-
crystallized with the irreversible fluoromethyl ketone inhibitor
Mor-Leu-Hpq was used as a template [28]. The mature protein
full-length sequence identity of 60% and sequence similarity of
74% between CPB2.8∆CTE and cruzain was reasonable for
the generation of a qualified homology model. The resulting
homology model of CPB2.8∆CTE showed a Cα RMSD value of
0.699 Å compared to its template structure. The homology
model was then structurally compared to bovine cathepsin B
(BtCatB, PDB ID 1QDQ) by superimposing the two protein
structures. The locations of the amino acids that differ between
L. mexicana CPB and BtCatB are given in Table 1.
Comparison of the active sites indicates high residue similarity
for the S1’ and the catalytic triade but also a significant residue
difference between CPB2.8∆CTE and BtCatB in the S2 subsite
(Y210E; numbering is according to the mature CPB2.8
enzyme, Table 1). This difference in the S2 subsite of the
parasite and the host enzyme provides optimism for lead
compound optimization approaches for the development of
selective inhibitors that target the parasite protein.
HTS of recombinant CPB2.8∆CTE for inhibitors
To identify inhibitors of CPB2.8∆CTE that could be lead
candidates for further optimization in an antiparasitic drug
discovery program, a screening library in a competition assay
involving Z-F-R-AMC as a substrate was tested. The library
was set up as depicted in Figure 1. Starting from a database of
2 million commercially available compounds, we used the
molecular descriptor BCUT metrics developed from the work of
Burden and Pearlman [29-31] to select a structurally diverse
subset. This subset was further filtered by application of a
property filter (see Experimental Section for details), which
decreased the number of compounds in the library to 74,339
entities. This library was used to screen CPB2.8∆CTE at single
compound concentration of 10 µM. During hit verification (IC50
determination from liquid compound stock) BtCatB was used in
a counter assay to provide information on the selectivity profile
of the inhibitors. We used BtCatB in the counter assay for
practical reasons because in parallel to this study we ran a
screening on Eimeria tenella Cathepsin B-like enzyme also
using BtCatB in the counter screen [23].
This assay resulted in 82 verified hits exhibiting an IC50 ≤ 30
µM on CPB2.8∆CTE. These hits were then subjected to an in
vitro hit confirmation procedure. Thus, IC50 determination was
replicated by using freshly dissolved compound from either
solid stock taken from the supplier or in-house resynthesized
solid stock, in order to eliminate potential false positives
caused by, e.g., degradation products. To confirm the actual
molecular structure in the test tube with the molecular structure
stored in the database, the relevant hit compounds were
analyzed by NMR spectroscopy and LCMS. Subsequently, the
kinetic aqueous solubility of the hits was determined using
nephelometry. In summary, 36 compounds could be ordered in
sufficient amounts from the suppliers. All of these 36 confirmed
hits passed the solubility criteria (solubility up to 30 µM) and the
quality control criteria.
Biochemical results of the tested compounds revealed a
broad activity range (IC50) against CPB2.8∆CTE, from a high
micromolar range down to double-digit nanomolar potency. A
total of 15 compounds exhibited IC50 values below 1 µM on
CPB2.8∆CTE while they showed no activity on BtCatB (IC50 >
30 µM). The remaining 21 compounds also showed IC50 values
below 1 µM on CPB2.8∆CTE and were active on BtCatB as
well (IC50 ≤ 30 µM). While thiosemicarbazones were present in
both groups, semicarbazones were exclusively found in the
selective group (IC50 < 1 µM on CPB2.8∆CTE and IC50 > 30 µM
on BtCatB) and nitriles were exclusively found in the less
selective group (IC50 < 1 µM on CPB2.8∆CTE and IC50 ≤ 30 µM
on BtCatB). Ki values were calculated for the four most active
compounds, which were also qualified as confirmed leads.
Structures (Figure 2), warhead-type, IC50 and Ki values toward
Table 1. Key active site residues of L. mexicana
CPB2.8ΔCTE, BtCatB, and for comparison human
cathepsin B (HsCatB).
Proteasea S2 Subsite S1 Subsite Catalytic triade S1’ Subsite
CPB2.8ΔCTE L70, Y210,V212 L68, M69,A140, G165
C26, H164,
N184 Q20, W186
BtCatB S77, E245, V247 E75, P76,A173, A200
C29, H199,
N219 Q23, W221
HsCatB A77, E245, V247 Y75, P76,A173, A200
C29, H199,
N219 Q23, W221
[a] Numbers refer to the mature sequences.
Y210 from CPB2.8ΔCTE and E245 from CatB are highlighted in bold.
doi: 10.1371/journal.pone.0077460.t001
HTS of Leishmania mexicana Cysteine Protease CPB
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CPB2.8∆CTE are presented in Table 2 together with the data
toward BtCatB.
The leads belong to three different warhead-types, namely
thiosemicarbazones (CP247129, CP247128), nitriles
(CP241026) and semicarbazones (CP229988). The
thiosemicarbazone CP247129 displayed an IC50 on
CPB2.8∆CTE in the nanomolar range while the compound was
inactive on BtCatB (IC50 > 30 µM). Conversely, the
thiosemicarbazone (CP247128) exhibited an IC50 on both
CPB2.8∆CTE and on BtCatB in the nanomolar range (Table 2).
The nitrile CP241026 was approximately ten times less active
on CPB2.8∆CTE (Ki = 570 nM) compared to both
thiosemicarbazones but exhibited weak activity on BtCatB (IC50
= 13.8 µM). The most potent and specific CPB2.8∆CTE
inhibitor identified in the assay was the semicarbazone
CP229988 with a Ki of 5 nM and an IC50 > 30 µM toward
BtCatB.
Covalent Docking Analysis
Covalent docking [24] as implemented in GOLD 5.0.1 was
employed to predict the protein/ligand binding interactions of
the four lead structures using the previously generated
homology model of mature CPB2.8∆CTE and the publicly
available X-ray crystal structure of BtCatB (PDB ID 1QDQ)
[33]. The basic chemical reactions of the warheads proposed
for covalent docking are shown in Figure 3. The accordingly
modified compounds were docked independently into the
binding site of both cysteine proteases (see Experimental
Section for details). In order to visualize surface regions, the
program MOLCAD [34] was applied. Compound CP247129
was selected for covalent docking studies due to its differences
in inhibitory activity on CPB2.8∆CTE (Ki = 40 nM) compared to
BtCatB (IC50 > 30 µM). As expected, a significant difference
between the orientation of the top ranked poses of CP247129
covalently bound to the active site of CPB2.8∆CTE (Figure 4A)
and BtCatB (Figure 4B) was observed. In Figure 4A the 4-
Figure 1.  Discovering the lead compounds against L.  mexicana CPB2.8∆CTE.
Set up of the screening library and filtering steps during hit enrichment. Four confirmed leads were finally identified by the hit
enrichment workflow: one of the warhead-type semicarbazone, two of the warhead-type thiosemicarbazone and one of the
warhead-type triazine nitrile.
doi: 10.1371/journal.pone.0077460.g001
HTS of Leishmania mexicana Cysteine Protease CPB
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methoxy phenyl portion of CP247129 is oriented toward the
deep S2 subsite and the furanyl moiety occupies the shallow
S1 subsite. The thiosemicarbazone scaffold was assumed to
interact via a 1,2-polar addition of the catalytic C26 to the C=S
group of CP247129 (Figure 3A) [23,35]. Thus, the resulting
tetrahedral transition state was used as the initial conformation
of the thiosemicarbazone scaffold for covalent docking. The
thiole group represents a prochiral center and as it is a priori
 not known which isomer resembles the most active transition
state, both possible stereo isomers were generated for the
covalent docking procedure. In Figure 4A the top ranked S-
isomer of CP247129 is shown, and the covalent bond between
the C26 sulfur and the transformed thiocarbonyl carbon is
marked by a yellow arrow. The NH2 group of the
thiosemicarbazone scaffold fits close to the carbonyl of G24.
The distance between the nitrogen and the oxygen of the G24
Figure 2.  Confirmed lead structures inhibiting CPB2.8∆CTE of L.  mexicana.
Two thiosemicarbazones (CP247129 and CP247128), one nitrile (CP241026) and one semicarbazone (CP229988).
doi: 10.1371/journal.pone.0077460.g002
HTS of Leishmania mexicana Cysteine Protease CPB
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carbonyl was calculated to be 2.18 Å, supporting a hydrogen
bond between the two atoms. The reaction of C26 to the C=S
Table 2. Confirmed lead structures inhibiting CPB2.8∆CTE
of L. mexicana.
Compound Warhead-Type IC50 [µM] Ki [µM]a
  CPB2.8ΔCTE BtCatB CPB2.8ΔCTE
CP247129 Thiosemicarbazon 0.07 ± 0.04 >30 0.04 ± 0.02
CP247128 Thiosemicarbazon 0.06 ± 0.01 0.02 ± 0.004 0.04 ± 0.02
CP241026 Nitrile 1.1 ± 0.15 13.8 ± 4.5 0.57 ± 0.08
CP229988 Semicarbazone 0.01 ± 0.003 >30 0.005 ± 0.002
[a] assuming compounds are competitive inhibitors.
Two thiosemicarbazones, one nitrile and one semicarbazone. BtCatB was used in
the counter assay to test the selectivity profile. Results are expressed as mean
IC50 ± SD from three independent experiments and as calculated Ki ± SD using
the Cheng-Prusoff equation [29].
doi: 10.1371/journal.pone.0077460.t002
group would be further assisted by the transfer of the H164
proton to the thiosemicarbazone sulfur. Figures 4A to 4H also
show the MOLCAD lipophilic potential (LP) surfaces of the
corresponding binding sites. The color for LP ranges from
brown (highest lipophilic area of the surface) to blue (highest
hydrophilic area of the surface). As depicted in Figure 4A, the
4-methoxy-phenyl-2-furanyl portion of CP247129 is oriented to
a brown region, suggesting that hydrophobic substituents may
be favored in the S1 and S2 subsite of CPB2.8∆CTE. In
contrast, the 4-methoxy-phenyl-2-furanyl portion of CP247129
covalently bound to the C29 thiolate of BtCatB is oriented to
the primed subsites as depicted in Figure 4B. The unprimed
subsites of BtCatB show a green LP region, suggesting that
hydrophilic groups would be favorable due to the Y210E/L70S
exchange in the S2 subsite. Figure 4B clearly shows that key
hydrogen bonding and hydrophobic contacts that are
established in the complex of the active S-enatiomer with
CPB2.8∆CTE are completely disrupted. These observations
could explain the lack of potency of CP247129 toward BtCatB.
Figure 3.  Schematic representation of the covalent binding of warheads for the covalent docking process.  Atoms that form
the covalent bond are labeled P in the protein and L in the ligand. Covalent bonds between P and L are indicated with dashed lines.
(a-d) Reaction between thiosemicarbazone[30], nitrile[31] and semicarbazone warhead of the ligand and the catalytic cysteine
residue of the protein.
doi: 10.1371/journal.pone.0077460.g003
HTS of Leishmania mexicana Cysteine Protease CPB
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Figure 4.  Covalent docking solutions of thiosemicarbazone-, nitrile- and semicarbazone-based inhibitors in the active site
of the L.  mexicana CPB2.8∆CTE homology model (A, C, E, G) and the X-ray structure of BtCatB (B, D, F, H).
The transparent solvent accessible surface of the active sites is colored by lipophilic potential. The color ramp ranges from brown
(highest lipophilic area of the surface) to blue (highest hydrophilic area of the surface). The relevant cysteine residue has been
excluded from surface generation for visibility reasons of the covalent bond between the enzyme and the inhibitor molecule.
Relevant amino acids of the active sites and the corresponding inhibitors are depicted in capped-stick representation and colored by
atom type. The yellow arrow marks the covalent bond between the catalytic cysteine and the inhibitor. A: CP247129 covalently
docked into the active site of CPB2.8∆CTE, B: CP247129 covalently docked into the active site of BtCatB, C: CP247128 covalently
docked into the active site of CPB2.8∆CTE, D: CP247128 covalently docked into the active site of BtCatB, E: CP241026 covalently
docked into the active site of CPB2.8∆CTE, F: CP241026 covalently docked into the active site of BtCatB, G: CP229988 covalently
docked into the active site of CPB2.8∆CTE, H: CP229988 covalently docked into the active site of BtCatB.
doi: 10.1371/journal.pone.0077460.g004
HTS of Leishmania mexicana Cysteine Protease CPB
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A similar binding mode to CPB2.8∆CTE could be observed
for the top ranked S-isomer of CP247128 when compared to
CP247129 (Figure 4C). The hydrophobic 2-phenyl-1H-indole
portion occupies the S1 and S2 subsite while the nitrogen of the
indole is oriented near the carbonyl oxygen of G67. The
calculated distance of 2.88 Å accounts for a stabilizing
hydrogen bond. Furthermore, probably stabilizing hydrogen
bonds of the thiolate intermediate can be established as
described for CP247129. The MOLCAD lipophilic potential
predicts a brown region for the S1 and S2 subsites, which
satisfactorily match the hydrophobic 2-phenyl-1H-indole portion
of CP247128. An unexpected binding mode was observed for
the top ranked S-isomer of CP247128 covalently docked into
the active site of BtCatB (Figure 4D). Due to the green LP
region of the first two unprimed subsites of BtCatB, the phenyl
portion of CP247128 was placed into the S1’ subsite while the
nitrogen of the indole moiety fits close to the oxygen of the
M194 carbonyl with a calculated distance of 3.09 Å. This
covalent docking solution of CP247128 allows key hydrogen
bonds of the tetrahedral transition state, and thus could explain
the nanomolar potency of CP247128 toward both
CPB2.8∆CTE and BtCatB.
Figure 4E shows the top ranked pose of the triazine nitrile
CP241026 covalently bound to the active site of CPB2.8∆CTE.
A thioimidate moiety formed by covalent interaction between
the nitrile warhead and the C26 thiolate in the CPB2.8∆CTE
catalytic site was assumed and generated for the covalent
docking procedure (Figure 3B) [36]. The cyclohexyl group is
placed into the hydrophobic S2 subsite while the 2-methoxy-
pyridyl moiety occupies the S1’ subsite. The 3-pyridyl
secondary amino group of CP241026 is oriented close to the
oxygen of the D65 carbonyl group, suggesting a hydrogen
bond between N and O with a calculated distance of 2.41 Å. A
different binding mode was observed for the top ranked
covalent docking solution of CP241026 bound to the active site
of BtCatB (Figure 4F). The green LP surface of the S2 subsite
forces the hydrophobic cyclohexyl group to twist, which
resulted in unfavorable BtCatB interactions and probably weak
inhibitory activity of CP241026 toward the enzyme.
Although, it seems to be accepted that peptidyl
semicarbazones inhibit cysteine proteases through the
formation of a reversible tetrahedral adduct by attack of the
thiolate on the C-5 carbon[37] (Figure 5) covalently docking the
semicarbazone CP229988 into the active site of the
CPB2.8∆CTE homology model and the BtCatB X-ray structure
using the tetrahedral adduct of the thiolate and the C-5 carbon
as the initial docking conformation results in poor docking
scores only. This was also true for the parent ketone
benzopyran-2-on of CP229988. Thus, the only logical site of
covalent interaction with CPB2.8∆CTE in CP229988 is the C-2
double bond (Figure 5) [38]. Indeed, using the C-2 carbon for
the docking led to a docking solution with a reasonable docking
score as shown in Figure 4G, which shows the top ranked pose
of the semicarbazone CP229988 covalently bound to the active
site of CPB2.8∆CTE. A thiohemiketal between the carbonyl
group of the semicarbazone scaffold and the C26 thiolate in the
CPB2.8∆CTE catalytic site was assumed (Figure 3C) [38].
Because the carbonyl group represents a prochiral center, both
possible stereoisomers were generated for the covalent
docking procedure. In Figure 4G the top ranked S-isomer of
CP229988 is shown, and the covalent bond between the C26
sulfur and the C-2 carbon is marked by a yellow arrow. The
amino group of the semicarbazone scaffold fits close to the
carbonyl of G24 and the calculated distance of 2.18 Å suggests
a stabilizing hydrogen bond. The reaction of C26 to the
carbonyl group would be further assisted by the transfer of the
H164 proton to the semicarbazone oxygen. The benzopyran-2-
ylidene portion of CP229988 is oriented to the hydrophobic S2
subsite, while the benzimidazol-2yl moiety occupies the S1
subsite of CPB2.8∆CTE. In contrast, the (1H-benzimidazol-2-
yl)-2H-1-benzopyran-2-ylidene portion of CP229988 covalently
bound to the C29 sulfur of BtCatB is oriented to the primed
subsites as depicted in Figure 4H. No top ranked covalent
docking pose could be obtained for CP229988 and BtCatB. In
addition, Figure 4H clearly shows that key hydrogen bonding
and hydrophobic contacts that are established in the
tetrahedral complex of the active S-enantiomer with
CPB2.8∆CTE are completely disrupted.
Discussion
In this study, 74,339 structurally diverse compounds coming
from a general screening library have been tested as inhibitors
of a recombinant form of the cathepsin L-like cysteine protease
CPB present in the parasite L. mexicana (CPB2.8∆CTE). In a
separate assay, the compounds were evaluated for their ability
to inhibit cathepsin B from bovine spleen. BtCatB was chosen
over the higly similar HsCatB because of easy accessibility.
Two unexpected results emerge from this study. First,
molecules with novel cysteine protease warheads were not
identified in this study. This is startling, given the effort devoted
to identify inhibitors bearing covalent reversible warheads in
screening libraries [24]. Because the structurally diverse
screening set was filtered from a general purpose screening
library of 2,000,000 compounds, we assumed to find more
suitable warheads. Even taking into account the lack of target
bias in the chemotypes represented in it, the result suggests
that potent covalent reversible inhibition of CPB2.8∆CTE is
limited to only a few warheads. Second, only compounds from
the thiosemicarbazone and semicarbazone warhead-type were
identified as specific, reversible inhibitors of CPB2.8∆CTE but
with no activity against BtCatB (IC50 > 30 µM); the selectivity
ratio (CPB2.8∆CTE/BtCatB) was <0.00033 for the most active
inhibitor CP229988. These two findings will be considered in
turn.
The lack of novel covalent reversible acting warheads
identified in the CPB2.8∆CTE HTS highlights the limitations of
screening a relatively small and unbiased library within a large
chemical possibility space. The screening library was designed
for general use, with no single family of targets in mind, and it
is not dominated by any one chemotype. Finding new
chemotypes from libraries for which there is no ligand bias for
the protein is an ongoing challenge in the field [39,40]. This
explains the good track record of HTS against chemically well-
explored targets such as G-protein coupled receptors and
kinases and its often limited results against new genomic
HTS of Leishmania mexicana Cysteine Protease CPB
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targets [41]. Expanding the library by even an order of
magnitude, however, and adding chemotypes from different
sources, will only partially address this chemical space problem
[42,43]. Another solution would be to simply screen at higher
concentrations of compound, but this presents logistical
difficulties, including exhaustion of source material, insolubility
of compound in the assay, and an increase in the number of
artifactual hits. An alternative is to prioritize a small subset of
more likely chemotypes for careful testing, often at higher
concentrations. One approach to do this is by looking for
complementary fits of particular library molecules to the
structure of the target, as is afforded by molecular or covalent
docking [24]. However, our findings using the unbiased library
provide good evidence that the three warhead types found to
inhibit are perhaps those compound groups most worth pursing
in the search for drugs against these cysteine proteases.
We used in this study covalent docking to study the binding
mode of the newly identified inhibitors with their protein targets
CPB2.8∆CTE and BtCatB. It is well established that the
primary determinant of specificity for papain and cathepsins B
and L is the S2 subsite [12,44-47]. Hydrophobic residues are
preferred at the P2 position of substrates for papain and
cathepsin L, but cathepsin B also accepts basic residues there.
This difference is due to the presence of a glutamic acid at S2
of cathepsin B [12,46-48]. Covalent docking studies using the
homology model of CPB2.8∆CTE reveal that the
semicarbazone CP229988 and the thiosemicarbazone
CP247129 have strict preference for the S1 to S2 subsites. A
tyrosin (Y210) is located at the bottom of S2, which results in a
much larger hydrophobic S2 subsite in the CPB2.8∆CTE
enzyme compared with BtCatB. This is consistent with the
finding that peptides containing hydrophobic amino acids at the
P1 position, with hydrophobic and basic amino acids at P2 and
P3, respectively, were resistant to hydrolysis by CPB2.8∆CTE
but nevertheless had affinities in the nanomolar range [49].
Conversely, compounds CP229988 and CP247129 displayed
only poor docking scores when covalently docked into the X-
ray structure of BtCatB. These results suggest that specific
inhibition of this cathepsin B relies on the primed subsite of the
enzyme [50]. Two histidines located side by side in a large
occluding loop form an area of strong positive charge in the S2’
subsite of BtCatB, which can be addressed by inhibitors with a
negatively charged C-terminal group. In addition, the deep S1’
subsite of BtCatB prefers large hydrophobic residues of an
inhibitor while cathepsin L has an opposite trend, favoring
amino acids with small or long but non-branched site chains
[51]. These observed differences in binding interactions and
the corresponding difference in covalent docking ranks provide
a cogent rationale for the observed lack in the BtCatB inhibitory
activity of CP247129, CP229988 and the triazine nitrile
CP241026.
An encouraging result to emerge from this study was the
discovery of three new non-peptide scaffolds of competitive
inhibitors of L. mexicana CPB2.8∆CTE, with Ki values ranging
from 5 nM to 570 nM. The covalent docking studies have
provided an understanding of the importance of the
determinants of inhibitory activity in CPB2.8∆CTE, and, as a
result, we found that the docking ranks paralleled the activities
on a qualitative level. Thus, this methodology could be
employed as a guide in selecting new molecules.
Semicarbazones, thiosemicarbazones and triazine nitriles
are warhead-types of compound groups already known to
Figure 5.  Semicarbazone scaffold and numbering of atoms.  
doi: 10.1371/journal.pone.0077460.g005
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contain cysteine protease inhibitors. However, the four lead
compounds identified by this study are novel inhibitors, with the
semicarbazone CP229988 being shown to have good activity
and high specificity. Further research is needed to elucidate
whether the potent inhibition in the biochemical assays is
translated into efficacy also against the parasite itself in
appropriate biological assays. The Ki values of lead
compounds are, however, in the nanomolar range, which is a
promising starting point for further lead optimization to generate
compounds that could be candidate drugs.
Experimental Section
Reagents
All chemicals and the irreversible cysteine protease inhibitor
E-64 (1-[N-[(L-3-trans-carboxyoxirane-2-carbonyl)-L-
leucyl]amino]-4-guanidinobutane) were from Sigma-Aldrich
Inc., St. Louis, MO, USA, unless stated otherwise. The Z-F-R-
AMC substrate was from Bachem.
Homology protein modelling
The sequence of mature L. mexicana CPB2.8∆CTE was
used to search the Brookhaven Protein Data Bank (PDB). To
build the homology model, the crystal structure of cruzain in
complex with the irreversible fluoromethyl ketone inhibitor Mor-
Leu-Hpq was used as the template: PDB entry ID 1EWP [28].
Homology models were calculated using the program Modeller
implemented in the Insight II software package (Accelrys Inc.
San Diego, CA, USA) [52]. All calculations were carried out
under default conditions. For the alignment of the CPB2.8∆CTE
sequence to the template, the BLOSUM 62 matrix implemented
in Modeller’s ALIGN123 module was taken. Four homology
models were generated using the default conditions with the
highest optimization level, and subsequently four additional
structures were generated with a high loop refinement for each
of the four initial homology models. In summary, 16 homology
models were built to ensure the generation of the highest
possible structure quality. The corresponding model with the
lowest value of PDF violations in combination with the lowest
energy value was selected for validation. The quality of the
models was validated using the ProStat and Profiles3D method
implemented in the Insight II software package. Disulfide
bridges were checked and assigned manually using the Sybyl
6.8 software package (Tripos Inc., St. Louis, MO, USA).
Enzyme source
A major cysteine protease (CPB) of L. mexicana that is
predominantly expressed in the amastigote life cycle form that
causes disease in mammals was overexpressed in Escherichia
coli. The CPB enzyme was expressed as an inactive pro-form
lacking the characteristic C-terminal extension, designated
CPB2.8∆CTE. Purification from inclusion bodies to apparent
homogeneity and activation of the recombinant enzyme was
described previously [21]. The enzyme concentration
determined by active site titration with E-64 was found to be 6
μM. The portion of active enzyme recovered was approximately
30% of the total recombinant enzyme [25]. Bovine cathepsin B
(BtCatB, EC 3.4.22.1) was obtained from Sigma-Aldrich Inc.,
St. Louis, MO, USA.
Screening library
The HTS library used against CPB2.8∆CTE and bovine
cathepsin B (BtCatB) was a collection of 74,339 small
molecules acquired from commercial vendors (Asinex, Ltd.,
Moscow, Russia; Akos Consulting & Solutions GmbH, Basel,
Switzerland; ChemBridge Corporation, San Diego, CA;
Chemical Diversity Labs, Inc., San Diego, CA; Enamine, Ltd.,
Kiev, Ukraine; InterBioScreen, Moscow, Russia; LifeChemicals,
Inc., Burlington, ON, Canada; Maybridge, Cambridge, United
Kingdom; Otava, Kiev, Ukraine; Specs, Delft, Netherlands;
TimTec Corp., Newark, NJ; and Vitas-M Laboratory, Ltd.,
Moscow, Russia). The 74,339 compounds were selected from
a 2 million vendor ISIS database (Symyx Technologies, Inc.,
Sunnyvale, CA) using the solutions module implemented within
the software tool SYBYL, version 6.8 (Tripos, Inc., St. Louis,
MO, USA). Molecules that contained atoms other than C, O, H,
N, S, P, F Cl, Br, or I, which had a molecular mass of >450 Da
or which possessed more than eight rotatable bonds were
removed from the data set. Filtering tasks were done using the
CACTVS software package [53]. The purity of all screening
compounds used was >90%.
Chemicals
CP247128 was ordered from InterBioScreen, Moscow,
Russia; the IUPAC name is 2-phenyl-1H-indole-3-carbaldehyde
thiosemicarbazone (purity of >95%); CP247129 was also
ordered from InterBioScreen; the IUPAC name is 5-(4-
methoxy-phenyl)-2-furanyl-2-carbaldehyde thiosemicarbazone
(purity of >95%); CP241026 was ordered from Vitas-M
Laboratory, Ltd., Moscow, Russia; the IUPAC name is 4-
(cyclohexylamino)-6-[(2-methoxy-3-pyridinyl)amino]-1,3,5-
triazine-2-carbonitrile (purity of >95%). CP229988 was ordered
from Chemical Diversity Labs, Inc., San Diego, CA; the IUPAC
name is 3-[(1H-benzimidazol-2-yl)-2H-1-benzopyran-2-
ylidene]-2-carbaldehyde semicarbazone (purity of >95%).
Determination of IC50 values
The activities of CPB2.8∆CTE and BtCatB were measured in
a homogeneous fluorescence endpoint assay using Z-F-R-
AMC as substrate, modified from published methods [17,54].
The fluorophore AMC (7-amino-4-methylcoumarin) is released
by active cysteine protease, and can be detected at 360 nm
excitation and 465 nm emission. The assay was optimized for
automated high throughput screening on a Biomek FX
workstation (Beckman Coulter). All assays were carried out in
black 384 well plates at room temperature (22°C). Each plate
contained 24 controls in the 23rd and 24th rows of the plate,
including 8 positive controls and 8 blanks (without enzyme) as
well as 8 inhibitor controls. E-64 was used as standard
inhibitor. A final concentration of 10 µM of E-64 resulted in a
complete inhibition of protease activity. Test compounds
available as 10 mM stock solutions in DMSO were diluted
further in DMSO, except for the last 1:10 step, which was done
in H2O to lower the DMSO concentration in the assay. Final
concentrations of the test compounds from 30 µM to 0.3 nM
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were used. For the L. mexicana CPB2.8∆CTE assay, 5 µl test
compound or 5 µl DMSO in acetate buffer (10% DMSO) was
added to each well of the microtiter plate. Subsequently, 25 µl
of a premix containing sodium acetate buffer (final
concentration [f.c.] 100 mM), titriplex II (f.c. 1 mM) (Merck,
Darmstadt, Germany), DTT (f.c. 10 mM) (Carl Roth GmbH,
Karlsruhe, Germany), triton (f.c. 0.01%) (Merck, Darmstadt,
Germany), BSA (f.c. 0.1 mg/ml) (PAA Laboratories GmbH,
Pasching, Austria) and enzyme was added to each well, except
the wells for the blanks, which include the premix without
enzyme. After an incubation time of 10 min, the reaction was
started by addition of substrate (20 µl Z-F-R-AMC; f.c. 20 µM).
The reaction was stopped after 35 min incubation at room
temperature by addition of 10 µl inhibitor E64 (f.c. 16.7 µM) and
enzyme activity was measured with a SpectraFluorPlus (Tecan
Inc., Durham, NC) plate reader using excitation at 360 nm with
emission at 465 nm. The assay procedure for BtCatB was the
same as for the CPB2.8∆CTE assay with the exceptions of the
final concentration of the substrate Z-F-R-AMC (100 µM) and
the stop of the assay using a stop buffer containing sodium
acetate and sodium chlorine acetate (f.c. 41.7 mM each).
The percentage enzyme activity was calculated using the
formula (V-B)/(C-B) x 100%, with V being the absorbance of
the assay containing the test compound, B being the
absorbance of the negative control (‘blank’) and C being the
absorbance of the positive control. In primary screening, all
compounds of the screening library were tested at 10 µM in
double point measurements. Z´ factors, which describe the
quality of an assay, were in the range of 0.85-0.99. The Z´
factor is defined in terms of four parameters: the means and
standard deviations of both the positive (p) and negative (n)
controls: Z´= 1-((3 x (STDEVp + STDEVn))/(MEANp - MEANn))
[55].
The theoretical hit limit for a HTS primary screen can be
calculated as MEAN + 3 x STDEV of inhibitions from diverse
compounds. If a normal distribution for inhibition is expected,
99.73% of inactive compounds are within this limit. In our case,
based on a preliminary screen of >3000 diverse compounds,
the hit limit was determined between 12.8% and 22.9%
inhibition. For practical reasons, screening hit limits are
normally set above this limit, aiming at approximately 0.2-0.4%
hits from a diverse library. Therefore, 50% inhibition at 10 µM
compound concentration compared to the positive controls was
considered a hit compound and were subjected to hit
verification (IC50 determination from liquid compound stock)
using CPB2.8∆CTE and BtCatB to get the activity profile of the
compounds. Hit confirmation (IC50 determination from freshly
dissolved solid compound stock) was performed for all
compounds with an IC50 ≤ 30 µM on CPB2.8∆CTE. Compound
concentrations used for IC50 determinations were as follows: 30
µM, 10 µM, 3 µM, 1 µM, 0.3 µM, 0.1 µM, 0.03 µM, 0.01 µM,
0.003 µM, 0.001 µM, and 0.0003 µM. Enzyme activities were
expressed as percentages of residual activity compared with
an uninhibited control and were plotted versus increasing
inhibitor concentrations. IC50 values were calculated using the
four-parameter equation model 205 and the option “unlock”
from the XLfit add-in (IDBS, Guildford, United Kingdom) in
Excel (Microsoft Corporation, Redmond, WA). All values are
mean values from at least three independent assays to ensure
statistically significant results.
Calculation of Ki values
Ki values of the proposed lead compounds were calculated
using the Cheng-Prusoff equation (Ki = IC50/(1 + [S]/Km) with [S]
= 20 μM and Km = 21.3 μM for CPB2.8∆CTE[32]. It is assumed
that the leads are reversible competitive inhibitors.
Compound solubility measurements
A 2-fold serial dilution of the compounds was performed (0.5
to 500 µM) in DMSO (Acros Organics, Fischer Scientific, Morris
Plains, NJ) and added in duplicate to 96-well microtiter plates.
Phosphate-buffered saline (PBS; pH 7.4) was added to give a
total volume of 200 µl and a final DMSO concentration of 5%
(vol/vol) in all wells. The plates were incubated at room
temperature for 22 min, and the relative solubilities of the
compounds were determined by measuring forward-scattered
light using a NEPHELOstar laser-based microplate
nephelometer (BMG Labtech GmbH, Offenburg, Germany).
Wells containing only buffer and 5% (vol/vol) DMSO were used
as controls. Data analysis was carried out using Excel
(Microsoft Corporation, Redmond, WA).
NMR and LC-MS analyses
Compound purity and molecular mass were confirmed by
liquid chromatography-mass spectrometry (LCMS)
experiments, which were performed on an Agilent LC7 MSD
(Mass Selective Detector) 1100 LC-MS (Agilent Technologies,
Santa Clara, CA). The liquid chromatography conditions were
as follows: a Zorbax SB (stable bound) C18 column, 1.8-µm
particle size, column dimensions of 4.6 by 30 mm, 0.1 µl/min
flow rate, gradient of 10 to 100% eluent B over 3 min (eluent A
was 95:5 H2O to CH3CN supplemented with 0.1% formic acid,
and eluent B was CH3CN), and a column temperature of 313 K.
MS detection was performed using an MSD 1100 electrospray
ionization (ESI) and atmospheric pressure ionization (API)
(Agilent Technologies, Santa Clara, CA) single quadrupole
mass spectrometer. Nuclear magnetic resonance (NMR)
spectroscopy was carried out on a Bruker Avance DRX 400
MHz NMR spectrometer (Bruker AXS, Madison, WI).
Covalent docking
Covalent docking was performed as previously described
[24]. Version 5.0.1 of the GOLD docking suite (The Cambridge
Crystallographic Data Centre) was used for covalent docking
studies [56,57]. The resulting docking solutions were ranked
based on the selected scoring function. In covalent mode, the
program assumed that there is just one atom linking the ligand
to the protein. Both protein and ligand files were set up with the
link atom included. During docking runs, the link atom in the
ligand is forced to fit onto the link atom in the protein. In order
to ensure that the geometry of the bound ligand was correct, an
angle-bending energy term for the link atom was included in
the calculation of the fitness score [56]. The above-described
covalent docking mode implemented in GOLD was applied for
all docking runs using standard default settings. The scoring
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function GoldScore was used in its modified version for
covalent docking. Protein structures were prepared according
to the GOLD user manual and ligand structures by application
of a CACTVS-based script [58]. If the electrophilic carbon atom
of a warhead represented a prochiral center, both possible
stereoisomers for the resulting compound were generated and
treated as distinct ligands for the further processing. The sulfur
atom of the C26 residue in the L. mexicana CPB2.8∆CTE
homology model and the sulfur atom of the C29 residue in the
BtCatB X-ray structure (PDB ID 1QDQ) were defined as the
link atoms for the covalent bond. The three-dimensional (3D)
illustrations of the covalent docking results depicted in Figure 4
were generated using MOLCAD [34].
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